Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China’s State Council Releases Policies On Bioindustry Development

This article was originally published in PharmAsia News

Executive Summary

China's State Council recently issued stimulus measures for speeding up local bioindustry development. Highlighted is the channelling of private capital to encourage establishment of investment institutions, as well as funds for biotechnology. The state will support the listing of local bioenterprises on the Small and Medium Enterprises Board and Growth Enterprise Board; encourage qualified biotech companies to raise funds via domestic or overseas listings, as well as issue corporate bonds, short-term financing bonds and medium-term notes; conduct share-transfer pilots and by tapping securities firms to promote equity rights circulation and broaden channels for investment. In addition, the government will set up coordination mechanisms at the ministry level to oversee key issues during the industry development. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC071962

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel